Heparin interactions: Uses, Dosage, Side Effects, Interactions, Warning
Heparin Interactions Checker – Drugs.com
Save
There are 224 drugs known to interact with
heparin, along with
7 disease interactions, and 1 alcohol/food interaction.
Of the total drug interactions,
58 are major, 143 are moderate, and 23 are minor.
Does heparin interact with my other drugs?
Enter other medications to view a detailed report.
- View all 224 medications that may interact with heparin
- View heparin alcohol/food interactions (1)
- View heparin disease interactions (7)
Most frequently checked interactions
View interaction reports for heparin and the medicines listed below.
- Major
- Moderate
- Minor
- Unknown
- Ativan (lorazepam)
- Benadryl (diphenhydramine)
- Cardizem (diltiazem)
- Colace (docusate)
- Combivent (albuterol / ipratropium)
- Coumadin (warfarin)
- Dilaudid (hydromorphone)
- Eliquis (apixaban)
- Lantus (insulin glargine)
- Lasix (furosemide)
- Lipitor (atorvastatin)
- Lopressor (metoprolol)
- Lovenox (enoxaparin)
- MiraLAX (polyethylene glycol 3350)
- Norco (acetaminophen / hydrocodone)
- Normal Saline Flush (sodium chloride)
- Norvasc (amlodipine)
- Paracetamol (acetaminophen)
- Percocet (acetaminophen / oxycodone)
- Phenergan (promethazine)
- Plavix (clopidogrel)
- Protonix (pantoprazole)
- Rocephin (ceftriaxone)
- Synthroid (levothyroxine)
- Tylenol (acetaminophen)
- Vitamin B12 (cyanocobalamin)
- Vitamin C (ascorbic acid)
- Vitamin D3 (cholecalciferol)
- Xanax (alprazolam)
- Zofran (ondansetron)
Heparin alcohol/food interactions
There is 1 alcohol/food interaction with heparin.
Heparin disease interactions
There are 7 disease interactions with heparin which include:
- peptic ulcer disease
- active bleeding
- hypertension
- prematurity
- renal dysfunction
- thrombocytopenia
- hyperkalemia
Report options
Loading…
QR code containing a link to this page
More about heparin
- heparin consumer information
- Compare alternatives
- Pricing & coupons
- Reviews (2)
- Latest FDA alerts (18)
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- Drug class: heparins
- Breastfeeding
- En español
Related treatment guides
- Angina
- Anticoagulation During Pregnancy
- Antiphospholipid Syndrome
- Deep Vein Thrombosis
Drug Interaction Classification
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
|---|---|
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
| Unknown | No interaction information available. |
The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Medical Disclaimer
Heparin (Porcine) Injection: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 10,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 10,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: Shape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 20,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 20,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 10,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 20,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 10,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 10,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL (1 mL) injection cartridge
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 10,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 20,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 10,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 10,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 10,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL injection solution
Color: clearShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 10,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 1,000 unit/mL injection solution
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
heparin (porcine) 5,000 unit/mL (1 mL) injection cartridge
Color: colorlessShape: Imprint:
This medicine is a colorless, clear, vial
Heparin sodium drug interactions with other drugs (compatibility) | Vidal.
ru
Heparin sodium drug interactions with other drugs (compatibility) | Vidal.ru – a directory of medicines
| ||||||||||||||
To reduce distortion in the determination of prothrombin time due to bolus intravenous heparin, an interval of at least 5-6 hours should be observed between the last administration of heparin and blood sampling.
5 times. Due to antiplatelet and antithrombotic properties, salicylates can potentiate the anticoagulant effect of heparin, which increases the risk of bleeding. In addition, the ulcerogenic effect of salicylates may increase the risk of bleeding from the gastrointestinal tract. The use of this combination is characterized by a high risk, therefore, if combination therapy is necessary, the expected benefit and potential risk should be carefully evaluated. If combined use is necessary, then constant monitoring of the patient’s condition is required. Our website uses cookies to improve your user experience and performance, as well as marketing activities.
By continuing, you agree to the use of cookies.
Ok
Order a drug
Heparin: instruction, price, analogues | ointment LLC “DKP “Pharmaceutical factory”
pharmacodynamics .
Heparin ointment is a direct-acting anticoagulant that has anti-inflammatory and local analgesic effects, prevents the formation of blood clots, promotes the resorption of blood clots.
Pharmacokinetics. Not determined.
prevention and treatment of thrombophlebitis of superficial veins; post-injection and post-infusion phlebitis, trophic ulcers of the lower leg, elephantiasis, superficial periphlebitis, lymphangitis; external hemorrhoids, inflammation of hemorrhoids after childbirth; superficial mastitis; localized infiltrates and edema, injuries and bruises without violating the integrity of the skin (including muscle tissue, tendons, joints).
the drug is used topically in adults.
In case of thrombophlebitis of the superficial veins of the extremities, apply the ointment to the affected area with a thin layer (at the rate of 0.5–1 g (2–4 cm of ointment) per area 3–5 cm in diameter) and gently rub into the skin 2–3 times a day for for 3-7 days until the signs of inflammation disappear.
The possibility of a long course of treatment is determined by the doctor.
In case of thrombosis of the hemorrhoidal veins, the ointment should be applied to a tissue napkin, which is directly applied to the hemorrhoids, and fixed with a bandage (it is possible to use a swab with an ointment applied to it, which should be inserted into the anus) 2-3 times a day until the symptoms disappear inflammation, on average 3-14 days. The possibility of long-term use is determined by the doctor individually.
hypersensitivity to any of the components of the drug. Ulcerative-necrotic processes, traumatic violation of the integrity of the skin, open infected wounds, hemorrhagic diathesis, purpura, thrombocytopenia, hemophilia, bleeding tendency.
redness, skin rash, urticaria, angioedema, hemorrhage, sometimes small pustules, vesicles or blisters may occur. Perhaps a local irritant effect, manifested in the form of burning, itching or slight swelling of the skin. The presence of methyl parahydroxybenzoate (E218) in the preparation can cause allergic reactions (possibly of a delayed type), when applied to large areas of the skin, systemic allergic reactions and hyperemia are possible.
with prolonged use of the ointment over large areas and the simultaneous use of oral drugs that affect the blood coagulation system and / or hematopoiesis, the clotting time and prothrombin time should be monitored. In case of need for a long course of treatment and application to large lesions in women aged ≥65 years, a similar control is recommended.
Should not be applied to open wounds in the presence of purulent processes. The use of the ointment is not recommended for deep venous thrombosis.
The drug should not be used for bleeding, mucous membranes, infected areas of the skin, inside the eye and around the eyes, on ulcers and blisters. In case of blood clotting disorders, it is not recommended to apply to large areas of the skin.
In case of thrombocytopenia and increased tendency to bleeding, the drug should be used under medical supervision.
Use during pregnancy or lactation . Do not use during pregnancy and lactation.
Children .
Do not use.
The ability to influence the reaction rate when driving vehicles or operating other mechanisms . Does not affect.
the action of the ointment is enhanced by anticoagulants, acetylsalicylic acid and other NSAIDs. The effectiveness of the ointment is reduced by digitalis preparations, tetracyclines, nicotine, antihistamines. The use of heparin may cause prolongation of prothrombin time in patients taking oral anticoagulants. It is not recommended to take the drug in combination with drugs for topical use, for example, with drugs containing tetracycline, hydrocortisone, salicylic acid, with anticoagulants.
due to the low level of absorption of heparin ointment, its overdose is impossible.
at 8-20°C, out of the reach of children.
Heparin ointment contains direct acting anticoagulant heparin as an active ingredient. This drug is used topically for the treatment and prevention of venous thrombosis of various origins, including post-injection phlebitis, periphlebitis and hemorrhoids.
Topically applied heparin has anticoagulant, anti-inflammatory and analgesic effects. Based on these properties, Heparin ointment can also be used in the treatment of mastitis, injuries and bruises, elephantiasis, trophic ulcers and lymphangitis.
Heparin ointment : an ageless classic
Heparin belongs to the group of glycosaminoglycan polysaccharides, its chemical structure is characterized by alternating disaccharides of hexuronic acid and hexosamine. At the same time, heparin is a highly sulfated molecule, and due to this property it has a very high negative charge, which allows it to bind to a wide range of positively charged molecules. The average molecular weight is in the range of 14-18 kDa (Page C., 2013).
2016 marks the 100th anniversary of the discovery of heparin by student Jay McLean under William Howell. Heparin received its name in 1918 (Rák K., 1998). It was given to this substance by two scientists, Emmett Holt and William Howell (Ong C.
S. et al., 2019). Already in the 40s of the twentieth century. Heparin began to be widely used clinically. It was the introduction of heparin into clinical practice that made it possible to make a breakthrough in cardiopulmonary surgery, the treatment of pulmonary embolism (pulmonary embolism), the management of patients with CRF (chronic renal failure) and severe poisoning, namely, it made it possible to perform hemodialysis (Messmore H.L. et al., 2004 ).
Heparin has been used as an anticoagulant for over 80 years. Despite its widespread use, the exact mechanism of the anticoagulant activity of heparin was not elucidated until the 1960s, and the specific polysaccharide sequence in the heparin molecule responsible for the anticoagulant effect was identified only in the 1980s (Page C., 2013). Subsequently, it was found that only a part of the heparin molecule has a high affinity for antithrombin and provides an anticoagulant effect, and low molecular weight heparin derivatives were synthesized (Messmore H.
L. et al., 2004).
Heparin ointment : what causes the anti-inflammatory properties
There is now strong evidence that heparin also exhibits anti-inflammatory activity, confirmed in studies both in vitro and in vivo 900 70 . It is important that in many cases the anti-inflammatory effect of heparin does not depend on its anticoagulant activity – drugs based on heparin are being searched for, having its anti-inflammatory properties, but not exhibiting an anticoagulant effect. Heparin exhibits anti-inflammatory activity through various mechanisms, including the neutralization of cationic mediators, inhibition of adhesion molecules and heparanase, inhibition of leukocyte migration to peripheral tissues (Page C., 2013).
Thus, mast cells contain many granules with inflammatory mediators. It has also been found that mast cells contain heparin granules. Subsequently, it was found that many proteins involved in the cascade of inflammatory reactions have heparin-binding domains in their structure, and heparin is able to inhibit the action of these proteins.
Thus, endogenous heparin may play an important role in controlling the local inflammatory response, and not just in the coagulation system. There is strong evidence for the clinical application of these properties of heparin. However, the use of heparin itself as an anti-inflammatory drug is currently limited by the anticoagulant activity of the molecule. At the same time, studies have shown that when using heparin in the form of inhalation, even at high doses, no anticoagulant effect was noted (Page C., 2013).
Heparin can inhibit the activation of a number of inflammatory cells. This effect is partly explained by the binding and neutralization of inflammatory mediators and enzymes released during the inflammatory response. It has also been found that several enzymes and cytotoxic mediators released from these cells, involved in the inflammatory response cascade and subsequent tissue damage and remodeling, are also inhibited by heparin, including elastase, cathepsin G, peroxidase eosinophils, eosinophilic cationic protein, some chemo- and cytokines.
Growth factors, including basic fibroblast growth factor and transforming growth factor beta-1, are involved in the regulation of smooth muscle proliferation (a feature of tissue remodeling observed in diseases such as AD, atherosclerosis and coronary stenosis) and are bound by heparin (thereby inhibited proliferation of smooth muscle cells). Heparin inhibits the proliferation of vascular smooth muscle cells, and this effect is independent of its anticoagulant action.
It is also known that heparin inhibits the degranulation of human mast cells in response to various stimuli and therefore inhibits the release of histamine. The cytotoxic effect of TNF-α-activated eosinophils on endothelial cells is also markedly inhibited by heparin, as is homotypic aggregation and chemotaxis of eosinophils in response to complement factor C5a, another inflammatory mediator. In addition, unfractionated heparin inhibits lipopolysaccharide-induced activation of endothelial cells (Page C., 2013).
It has been found that heparin binds to the surface of neutrophils and can inhibit their degranulation, aggregation, superoxide anion production, lysosomal enzyme activity, and the ability of neutrophils to activate platelets.
An important component of the inflammatory response is the adhesion (sticking) of inflammatory cells to the vascular endothelium and their subsequent diapedesis (movement) into tissues. Thus, heparin inhibits all stages of migration of pro-inflammatory cells into tissues and leukocyte-endothelial adhesion as in vitro and in vivo .
Studies have demonstrated the potential of heparin in the treatment of cystic fibrosis, asthma and COPD. In patients with allergic rhinitis after allergen exposure, topical heparin reduces the level of eosinophils in the nasal mucosa (Page C., 2013).
The possibility of using heparin in the treatment of oncological diseases is currently being studied. An analysis of studies on the use of heparin in cancer patients indicates an improvement in the survival rate.
It is believed that inhibition of the activity of heparanase, P- and L-selectin and tissue growth factor by heparin can contribute to the inhibition of angiogenesis and metastasis (Page C., 2013).
Heparin ointment : use in superficial venous thrombosis
Superficial venous thrombosis (SVT) is a common disease and a risk factor for thromboembolic complications. In this regard, it is important for the patient to timely seek medical help, establish a diagnosis, and select treatment in order to reduce significant complications (de Almeida M.J. et al., 2019). In 6–40% of patients, AVT can be combined with deep vein thrombosis. Among its complications, pulmonary embolism (PE) should be noted, which is observed in 22–46% of AVT cases. At the same time, in 20–33% of cases, small branch PE can be asymptomatic or masked by other diseases.
AVT is characterized by the formation of blood clots in the superficial veins with partial involvement or occlusion of the lumen and an inflammatory reaction along the vein.
A reddened, warm to the touch cord along the vein is visually determined. Patients complain of pain, there is also swelling of the tissues surrounding the area of thrombophlebitis. The clinical diagnosis is usually simple, but additional tests and examinations are needed to confirm the spread of thrombosis and possible thromboembolic complications (de Almeida M.J. et al., 2019).
Risk factors for developing AVT are varicose veins, immobilization, trauma, postoperative conditions, pregnancy, postpartum period, malignant neoplasms, some autoimmune diseases, use of oral contraceptives or hormone replacement therapy, advanced age, obesity, and previous thrombophlebitis.
Studies have shown that topical treatment with direct anticoagulants (heparin) and NSAIDs is effective in reducing the severity of AVT symptoms and preventing further spread of thrombosis (Nisio M.D., 2018).
Local application of heparin preparations provides not only a reduction in the severity of pain and swelling, but also a local inflammatory response (de Almeida M.
J. et al., 2019).
Place
Heparin ointment in the treatment of hemorrhoids
Another common condition for which Heparin ointment is effective is hemorrhoids. Hemorrhoids is considered one of the most common non-communicable diseases among the population. Its true prevalence is unclear due to the fact that a significant proportion of patients do not seek medical help and resort to self-medication. At 1990, according to an epidemiological study in the United States, the prevalence of hemorrhoids was 4.4%. At the same time, as a result of a study conducted in South Korea, it was revealed that the prevalence of hemorrhoids is 14.4%. And according to a study conducted in Austria, the prevalence of hemorrhoids in this country was 38.8%. It is believed that 25% of Britons and up to 75% of US citizens noted symptoms of hemorrhoids at least once in their lives (Lohsiriwat V., 2015).
Clinically, hemorrhoids are characterized by painless rectal bleeding with or without rectal mucosal prolapse.
Risk factors for hemorrhoids include pregnancy, advanced age, constipation, and many others, including a sedentary lifestyle, regular weight lifting (due to increased intra-abdominal pressure), and heredity. As a rule, hemorrhoids can be divided into two types: internal and external (Lohsiriwat V., 2015). As a result of clinical studies, it was found that most of the symptoms of hemorrhoids can be treated conservatively (Hall J.F., 2013). The most common complication of external hemorrhoids is hemorrhoid thrombosis. At the same time, patients note an increase in hemorrhoids, their soreness, itching, and discomfort in the anal region. Local heparin therapy has been considered an integral component of the conservative treatment of hemorrhoids for many years (Ogawa P., de Figueiredo J.C., 1966). It is the use of Heparin ointment that is pathogenetically determined in case of thrombosis of hemorrhoids.
Other Potential Uses for Heparin in
Heparin Ointment
In recent years, heparin has been shown to promote tissue repair and inhibit inflammation in burn patients.
One study included 100 patients under 15 years of age with 2nd degree burns and a burn area of 5-45%. They were divided into 2 groups of 50 people: patients of the 1st group received additional local heparin therapy, the 2nd group was a control and received standard treatment. The study found that patients who were additionally prescribed external heparin required lower doses of painkillers, and the use of heparin reduced the course of antibiotic therapy and reduced the number of dressings. In the heparin group, only 4 patients (8%) required skin grafting, compared to 10 (20%) in the control group. The lethal outcome in the control group was 5%, while in the heparin group it was 0%. Also, the use of heparin made it possible to reduce the length of stay of patients in the hospital. Thus, topical application of heparin for 5–7 days in patients with burns significantly accelerated healing and improved the condition of patients. In addition, local heparin therapy made it possible to reduce economic costs (by reducing the duration of hospital treatment and reducing the need for patients in skin grafting operations) (Venkatachalapathy T.